Baxter(US:BAX) Globenewswire·2025-12-01 21:16Core Viewpoint - A class action securities lawsuit has been filed against Baxter International, Inc. due to alleged securities fraud related to the company's product, Novum LVP, which reportedly has systemic defects leading to serious patient risks [1][2]. Group 1: Lawsuit Details - The lawsuit claims that Baxter's Novum LVP product has systemic defects causing malfunctions such as underinfusion, overinfusion, and non-delivery of fluids, posing risks of serious injury or death to patients [2]. - Baxter was allegedly aware of multiple device malfunctions, injuries, and deaths linked to these defects but failed to implement adequate remedial measures [2]. - The complaint suggests that Baxter's statements regarding the safety, efficacy, and sales prospects of the Novum LVP were materially false and misleading [2]. Group 2: Investor Information - Investors who suffered losses during the specified period (February 23, 2022, to July 30, 2025) have until December 15, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Legal Firm Background - Levi & Korsinsky, LLP has a history of securing significant recoveries for shareholders and is recognized as one of the top securities litigation firms in the United States [4].